Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

Ki vehet részt

• At least 18 years old at the time of signing the Informed Consent Form (ICF)
• Diagnosed with MG, classified as MGFA Class II-IVa, and judged by the investigator as unlikely to require respiratory support during the study
• At screening, the Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥ 5, with non-ocular items accounting for ≥ 50% of the total score, and GMG ≥ 11
• Inadequate response to conventional therapies or lack of effective treatment options, defined as disease recurrence or progression despite treatment with corticosteroids, immunosuppressants (e.g., azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A, methotrexate), or biologics (e.g., rituximab), and/or lack of effective treatment methods

Ki nem vehet részt

• Use of any approved immunosuppressive drugs not listed here within 12 weeks or 5 half-lives (whichever is longer) before screening, unless approved by the medical monitor
• Participation in any investigational trial involving non-biological agents within 4 weeks or 5 half-lives (whichever is longer) of the investigational product (IP) before screening
• Administration of live vaccines within 4 weeks before screening
• Presence of one or more significant concurrent diseases, as judged by the investigator, including but not limited to:; Poorly controlled diabetes; Chronic kidney disease stages IIIb, IV, or V; Severe chronic pulmonary disease (e.g., requiring supplemental oxygen) or respiratory failure
• Any history of CAR-T or TCE therapy targeting any antigen or BCMA-targeted therapy
• History of progressive multifocal leukoencephalopathy
• History of primary immunodeficiency (e.g., hypogammaglobulinemia) or hereditary complement deficiency
• Any severe medical condition or clinically significant laboratory abnormality that, in the judgment of the investigator or medical monitor, would compromise the patient's safe participation and completion of the study or may affect protocol compliance or interpretation of study results
• Participation in any investigational trial involving biological agents within 12 weeks or 5 half-lives (whichever is longer) of the IP before screening